Lv1
42 积分 2023-02-08 加入
151P: Real-world adjuvant treatment patterns in Chinese patients with resected stages I to III EGFR-mutated NSCLC: A multicenter observational study (ADDRESS, CATO-2001)
10天前
已关闭
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
13天前
已完结
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
1个月前
已完结
Massive bone grafts for long bone defects in battle casualties
2个月前
已关闭
Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in EGFR- mutated non-small cell lung cancer: systematic review and network meta-analysis
3个月前
已完结
First‐Line Third‐Generation EGFR Tyrosine Kinase Inhibitor Monotherapy for Advanced EGFR‐Mutated Non‐Small Cell Lung Cancer: A Systematic Review and Network Meta‐Analysis
3个月前
已完结
Adjuvant Chemotherapy Candidates in Stage I Lung Adenocarcinomas Following Complete Lobectomy
4个月前
已完结
The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma
5个月前
已完结
Adjuvant Chemotherapy Candidates in Stage I Lung Adenocarcinomas Following Complete Lobectomy
5个月前
已完结
The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival
5个月前
已完结
皖公网安备34019202002308
